Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06848075 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
A Phase 2 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 2
- Development phase
- 431
- Enrollment target
NCT06848075: Completed Phase 2 study, sponsored by Kallyope.
NCT06848075 is a Phase 2 study that has completed, run by Kallyope. The registered enrollment target is 431 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06848075, a Phase 2 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 431 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Interventions
- DRUG Placebo
- DRUG Elismetrep (K-304) Dose Level 1
- DRUG Elismetrep (K-304) Dose level 2
- DRUG Elismetrep (K-304) Dose level 3
- DRUG Elismetrep (K-304) Dose level 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2025-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06848075
The ClinicalTrials.gov registry entry for NCT06848075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 431 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06848075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06848075 about?
NCT06848075 is a clinical study titled "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine". This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
What is the current status of trial NCT06848075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 431 participants. The study started on 2025-03-05. Estimated completion is 2025-08-11.
What interventions are being tested in trial NCT06848075?
The interventions under investigation include: Placebo (DRUG), Elismetrep (K-304) Dose Level 1 (DRUG), Elismetrep (K-304) Dose level 2 (DRUG), Elismetrep (K-304) Dose level 3 (DRUG), Elismetrep (K-304) Dose level 4 (DRUG).
Who is sponsoring clinical trial NCT06848075?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.